OpenURL Connection Search

Select item for more details and to access through your institution.

MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE‐TYPE AND IS A THERAPEUTIC TARGET IN ADULT T‐CELL LEUKEMIA/LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 271, doi. 10.1002/hon.82_2630
By:
- Cheminant, M.;
- Lhermitte, L.;
- Bruneau, J.;
- Sicard, H.;
- Bonnafous, C.;
- Ortonne, N.;
- Genestier, L.;
- Gaulard, P.;
- Palmic, P.;
- Dussiot, M.;
- Waast, L.;
- Avettand‐Fenoel, V.;
- Brouzes, C.;
- Lepelletier, Y.;
- Asnafi, V.;
- Marçais, A.;
- Hermine, O.
Publication type:
Article
TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA
Published in:
Hematological Oncology, 2019, v. 37, p. 72, doi. 10.1002/hon.40_2629
By:
- Porcu, P.;
- Kim, Y.;
- Zinzani, P.;
- Sicard, H.;
- Azim, H.A.;
- Bagot, M.
Publication type:
Article
KIR3DL2 IS EXPRESSED IN PERIPHERAL T‐CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET.
Published in:
Hematological Oncology, 2019, v. 37, p. 204, doi. 10.1002/hon.21_2630
By:
- Cheminant, M.;
- Decroos, A.;
- Bruneau, J.;
- Carras, S.;
- Pelletier, L.;
- Martin, N.;
- Peri, V.;
- Guillot, F.;
- Paturel, C.;
- Sicard, H.;
- Bonnafous, C.;
- Lhermitte, L.;
- Molina, T.;
- Asnafi, V.;
- Genestier, L.;
- Gaulard, P.;
- Ortonne, N.;
- Hermine, O.
Publication type:
Article
MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE‐TYPE AND IS A THERAPEUTIC TARGET IN ADULT T‐CELL LEUKEMIA/LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 271, doi. 10.1002/hon.82_2630
By:
- Cheminant, M.;
- Lhermitte, L.;
- Bruneau, J.;
- Sicard, H.;
- Bonnafous, C.;
- Ortonne, N.;
- Genestier, L.;
- Gaulard, P.;
- Palmic, P.;
- Dussiot, M.;
- Waast, L.;
- Avettand‐Fenoel, V.;
- Brouzes, C.;
- Lepelletier, Y.;
- Asnafi, V.;
- Marçais, A.;
- Hermine, O.
Publication type:
Article
TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA
Published in:
Hematological Oncology, 2019, v. 37, p. 72, doi. 10.1002/hon.40_2629
By:
- Porcu, P.;
- Kim, Y.;
- Zinzani, P.;
- Sicard, H.;
- Azim, H.A.;
- Bagot, M.
Publication type:
Article
KIR3DL2 IS EXPRESSED IN PERIPHERAL T‐CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET.
Published in:
Hematological Oncology, 2019, v. 37, p. 204, doi. 10.1002/hon.21_2630
By:
- Cheminant, M.;
- Decroos, A.;
- Bruneau, J.;
- Carras, S.;
- Pelletier, L.;
- Martin, N.;
- Peri, V.;
- Guillot, F.;
- Paturel, C.;
- Sicard, H.;
- Bonnafous, C.;
- Lhermitte, L.;
- Molina, T.;
- Asnafi, V.;
- Genestier, L.;
- Gaulard, P.;
- Ortonne, N.;
- Hermine, O.
Publication type:
Article
Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results.
Published in:
Hematological Oncology, 2017, v. 35, p. 48, doi. 10.1002/hon.2437_31
By:
- Bagot, M.;
- Porcu, P.;
- Ram ‐ Wolff, C.;
- Khodadoust, M.;
- Basem, W.;
- Battistella, M.;
- Marie ‐ Cardine, A.;
- Vermeer, M.;
- Mathieu, S.;
- Whittaker, S.;
- Duvic, M.;
- Bensussan, A.;
- Paturel, C.;
- Bonnafous, C.;
- Thonnart, N.;
- Widemann, A.;
- Bonin, C.;
- Sicard, H.;
- Paiva, C.;
- Pilz, K.
Publication type:
Article
Diagnosis of cypress pollen allergy: in vivo and in vitro standardization of a Juniperus ashei pollen extract.
Published in:
Allergy, 2003, v. 58, n. 8, p. 808, doi. 10.1034/j.1398-9995.2003.00247.x
By:
- Hrabina, M.;
- Dumur, J.-P.;
- Sicard, H.;
- Viatte, A.;
- Andre, C.
Publication type:
Article
Latex allergy diagnosis: in vivo and in vitro standardization of a natural rubber latex extract.
Published in:
Allergy, 1997, v. 52, n. 1, p. 41, doi. 10.1111/j.1398-9995.1997.tb02544.x
By:
- Turjanmaa, K.;
- Palosuo, T.;
- Alenius, H.;
- Leynadier, F.;
- Autegarden, J.-E.;
- André, C.;
- Sicard, H.;
- Hrabina, M.;
- Tran, T. X.
Publication type:
Article
A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract.
Published in:
Allergy, 1994, v. 49, n. 5, p. 309, doi. 10.1111/j.1398-9995.1994.tb02273.x
By:
- Sabbah, A.;
- Hassoun, S.;
- Le Sellin, J.;
- André, C.;
- Sicard, H.
Publication type:
Article
KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.
Published in:
2018
By:
- Hurabielle, C.;
- Leboeuf, C.;
- Ram-Wolff, C.;
- Meignin, V.;
- Rivet, J.;
- Vignon-Pennamen, M.-D.;
- Bonnafous, C.;
- Sicard, H.;
- Fite, C.;
- Raffoux, E.;
- Arnulf, B.;
- Oksenhendler, E.;
- Sicre de Fontbrune, F.;
- Peffault de Latour, R.;
- Socié, G.;
- Bouaziz, J.-D.;
- Lebbé, C.;
- Bensussan, A.;
- Janin, A.;
- Bagot, M.
Publication type:
Letter to the Editor
KIR3 DL2 ( CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
Published in:
British Journal of Dermatology, 2016, v. 175, n. 2, p. 325, doi. 10.1111/bjd.14626
By:
- Battistella, M.;
- Janin, A.;
- Jean ‐ Louis, F.;
- Collomb, C.;
- Leboeuf, C.;
- Sicard, H.;
- Bonnafous, C.;
- Dujardin, A.;
- Ram ‐ Wolff, C.;
- Kadin, M.E.;
- Bensussan, A.;
- Bagot, M.;
- Michel, L.
Publication type:
Article

Found: 12

MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE‐TYPE AND IS A THERAPEUTIC TARGET IN ADULT T‐CELL LEUKEMIA/LYMPHOMA.

TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA

KIR3DL2 IS EXPRESSED IN PERIPHERAL T‐CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET.

MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE‐TYPE AND IS A THERAPEUTIC TARGET IN ADULT T‐CELL LEUKEMIA/LYMPHOMA.

TELLOMAK: T‐CELL LYMPHOMA ANTI‐KIR3DL2 THERAPY: AN OPEN LABEL, MULTI‐COHORT, MULTI‐CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T‐CELL LYMPHOMA

KIR3DL2 IS EXPRESSED IN PERIPHERAL T‐CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET.

Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results.

Diagnosis of cypress pollen allergy: in vivo and in vitro standardization of a Juniperus ashei pollen extract.

Latex allergy diagnosis: <em>in vivo</em> and <em>in vitro</em> standardization of a natural rubber latex extract.

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract.

KIR<sub>3</sub>DL<sub>2</sub> expression in patients with adult T-cell lymphoma/leukaemia.

KIR3 DL2 ( CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.